These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
139 related items for PubMed ID: 16883550
21. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity. Taub ME, Podila L, Ely D, Almeida I. Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365 [Abstract] [Full Text] [Related]
22. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA. Liu ZL, Onda K, Tanaka S, Toma T, Hirano T, Oka K. Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833 [Abstract] [Full Text] [Related]
23. MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer. Fung KL, Pan J, Ohnuma S, Lund PE, Pixley JN, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM. Cancer Res; 2014 Jan 15; 74(2):598-608. PubMed ID: 24305879 [Abstract] [Full Text] [Related]
24. Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Morita N, Yasumori T, Nakayama K. Biochem Pharmacol; 2003 Jun 01; 65(11):1843-52. PubMed ID: 12781336 [Abstract] [Full Text] [Related]
25. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM. Science; 2007 Jan 26; 315(5811):525-8. PubMed ID: 17185560 [Abstract] [Full Text] [Related]
27. Expression and functional activity of P-glycoprotein in passaged primary human nasal epithelial cell monolayers cultured by the air-liquid interface method for nasal drug transport study. Cho HJ, Choi MK, Lin H, Kim JS, Chung SJ, Shim CK, Kim DD. J Pharm Pharmacol; 2011 Mar 26; 63(3):385-91. PubMed ID: 21749386 [Abstract] [Full Text] [Related]
28. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin. Barthomeuf C, Grassi J, Demeule M, Fournier C, Boivin D, Béliveau R. Cancer Chemother Pharmacol; 2005 Aug 26; 56(2):173-81. PubMed ID: 15824923 [Abstract] [Full Text] [Related]
29. Over-expression of MDR1 in amrubicinol-resistant lung cancer cells. Takakuwa O, Oguri T, Ozasa H, Uemura T, Kasai D, Miyazaki M, Maeno K, Sato S. Cancer Chemother Pharmacol; 2011 Sep 26; 68(3):669-76. PubMed ID: 21128075 [Abstract] [Full Text] [Related]
30. Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells. Troutman MD, Thakker DR. Pharm Res; 2003 Aug 26; 20(8):1192-9. PubMed ID: 12948017 [Abstract] [Full Text] [Related]
31. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. Drug Metab Dispos; 1999 Aug 26; 27(8):866-71. PubMed ID: 10421612 [Abstract] [Full Text] [Related]
32. Different transport activity of human triallelic MDR1 893Ala/Ser/Thr variant and its association with herb extracts. Kim JH, Kim SR, Song IS, Shin HJ, Kim HS, Lee JH, Ko SG, Shin YC. Phytother Res; 2011 Aug 26; 25(8):1141-7. PubMed ID: 21287651 [Abstract] [Full Text] [Related]
33. Outward transfer of dopamine precursor L-3,4-dihydroxyphenylalanine (L-dopa) by native and human P-glycoprotein in LLC-PK(1) and LLC-GA5 col300 renal cells. Soares-Da-Silva P, Serrão MP. J Pharmacol Exp Ther; 2000 May 26; 293(2):697-704. PubMed ID: 10773046 [Abstract] [Full Text] [Related]
34. Interactions of human P-glycoprotein transport substrates and inhibitors at the drug binding domain: Functional and molecular docking analyses. Kadioglu O, Saeed ME, Valoti M, Frosini M, Sgaragli G, Efferth T. Biochem Pharmacol; 2016 Mar 15; 104():42-51. PubMed ID: 26807479 [Abstract] [Full Text] [Related]
35. Effect of PCB-126 on intracellular accumulation and transepithelial transport of vinblastine in LLC-PK1 and its transformant cells expressing human P-glycoprotein. Sasawatari S, Toki M, Horie T, Nakano Y, Ikeda T, Ueda K, Fujise H. J Vet Med Sci; 2004 Sep 15; 66(9):1079-85. PubMed ID: 15472471 [Abstract] [Full Text] [Related]
36. Effects of dietary flavonoids on the transport of cimetidine via P-glycoprotein and cationic transporters in Caco-2 and LLC-PK1 cell models. Taur JS, Rodriguez-Proteau R. Xenobiotica; 2008 Dec 15; 38(12):1536-50. PubMed ID: 18951251 [Abstract] [Full Text] [Related]
37. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG. J Pharmacol Exp Ther; 2002 Oct 15; 303(1):323-32. PubMed ID: 12235267 [Abstract] [Full Text] [Related]
38. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, Dey S. Biochemistry; 1998 Mar 17; 37(11):3594-601. PubMed ID: 9530286 [Abstract] [Full Text] [Related]
39. Inhibitors of mdr1-dependent transport activity delay accumulation of the mdr1 substrate rhodamine 123 in primary rat hepatocyte cultures. Hirsch-Ernst KI, Ziemann C, Rustenbeck I, Kahl GF. Toxicology; 2001 Oct 05; 167(1):47-57. PubMed ID: 11557129 [Abstract] [Full Text] [Related]
40. Effects of P-glycoprotein inhibitors on cadmium accumulation in cultured renal epithelial cells, LLC-PK1, and OK. Endo T, Kimura O, Sakata M. Toxicol Appl Pharmacol; 2002 Dec 15; 185(3):166-71. PubMed ID: 12498733 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]